Who
Pedro Beltran
President and CEO
Company insider
Files Form 4 as: President and CEO, BridgeBio Oncology Therapeutics.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Aug 2025
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,1251,047 at $3.94 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,1671,047 at $7.80 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,1671,047 at $7.80 | filing |
| 10 May 2026filed 12 May 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,103,837 at $0.00 | filing |
| 10 May 2026filed 12 May 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,103,837 at $0.00 | filing |
| 1 Apr 2026filed 5 May 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,4541,047 at $9.03 | filing |
| 1 Apr 2026filed 5 May 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,4541,047 at $9.03 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,670 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,670 at $0.00 | filing |
| 26 Aug 2025filed 28 Aug 2025 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —357,177 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.